Bipolar androgen therapy is being explored in trials with enzalutamide (Xtandi), olaparib (Lynparza), and nivolumab (Opdivo), explains Laura Sena MD, PhD.
In an interview during the SUO 2023 Annual Meeting, Laura Anne Sena, MD, PhD, highlighted ongoing trials exploring bipolar androgen therapy for the treatment of patients with prostate cancer. Sena is an instructor of oncology at Johns Hopkins Medicine.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.